Posted by Michael Wonder on 01 Feb 2024
Significant additional benefit of mavacamten in hypertrophic obstructive cardiomyopathy
1 February 2024 - In a dossier assessment in 2023, an additional benefit could not yet be proven due to unclear and missing information in the dossier.
The manufacturer BMS provided additional data in the comment process - with a positive result.
